- Home
- KPRX vs GSIW Comparison
KPRX vs GSIW Comparison
Compare KPRX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- GSIW
- Stock Information
- Founded
- KPRX 1998
- GSIW 2016
- Country
- KPRX United States
- GSIW Hong Kong
- Employees
- KPRX N/A
- GSIW N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GSIW
- Sector
- KPRX Health Care
- GSIW
- Exchange
- KPRX Nasdaq
- GSIW Nasdaq
- Market Cap
- KPRX 8.3M
- GSIW 8.3M
- IPO Year
- KPRX N/A
- GSIW 2023
- Fundamental
- Price
- KPRX $3.13
- GSIW $0.64
- Analyst Decision
- KPRX Strong Buy
- GSIW
- Analyst Count
- KPRX 1
- GSIW 0
- Target Price
- KPRX $10.00
- GSIW N/A
- AVG Volume (30 Days)
- KPRX 12.7K
- GSIW 1.9M
- Earning Date
- KPRX 05-09-2025
- GSIW 12-31-2024
- Dividend Yield
- KPRX N/A
- GSIW N/A
- EPS Growth
- KPRX N/A
- GSIW N/A
- EPS
- KPRX N/A
- GSIW N/A
- Revenue
- KPRX $20,000.00
- GSIW $1,313,795.00
- Revenue This Year
- KPRX N/A
- GSIW N/A
- Revenue Next Year
- KPRX N/A
- GSIW N/A
- P/E Ratio
- KPRX N/A
- GSIW N/A
- Revenue Growth
- KPRX N/A
- GSIW N/A
- 52 Week Low
- KPRX $2.51
- GSIW $0.35
- 52 Week High
- KPRX $5.55
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- KPRX 42.15
- GSIW 63.72
- Support Level
- KPRX $2.85
- GSIW $0.43
- Resistance Level
- KPRX $3.30
- GSIW $1.03
- Average True Range (ATR)
- KPRX 0.20
- GSIW 0.09
- MACD
- KPRX -0.02
- GSIW 0.03
- Stochastic Oscillator
- KPRX 16.34
- GSIW 41.22
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.